title: Autoimmunity and Graves' disease.
abstract: Current treatment options for Graves' hyperthyroidism and the related ophthalmopathy (GO) are not uniformly effective and carry with them potentially serious side effects. As a result, efforts have been focused on the development of novel therapies. Progress has been made, particularly in the production of thyroid-stimulating hormone receptor (TSHR) antagonists, as either monoclonal blocking antibodies or small-molecule ligands. In addition, rituximab (RTX) is the first targeted biological therapy to be studied as treatment for these conditions.
authors.affiliation: Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic School of Medicine, Mayo Clinic, Rochester, Minnesota, USA. bahn.rebecca@mayo.edu
authors.forename: R S
authors.initials: RS
authors.lastname: Bahn
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived / Q000494:pharmacology / Q000627:therapeutic use; D006111:Graves Disease / Q000276:immunology* / Q000628:therapy*; D049970:Graves Ophthalmopathy / Q000276:immunology / Q000628:therapy; D006801:Humans; D011989:Receptors, Thyrotropin / Q000037:antagonists & inhibitors / Q000276:immunology; D000069283:Rituximab
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D011989:Receptors, Thyrotropin; D000069283:Rituximab